References
- Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–534. [cited 2022 Feb 8]; Available from: https://coronavirus.jhu.edu/map-faq
- World Health Organization. Considerations for implementing and adjusting public health and social measures in the context of COVID-19 (interim guidance) [Internet]. World Health Organization. 2021 [cited 2022 Jan 28]. Available from: https://www.who.int/publications/i/item/considerations-in-adjusting-public-health-and-social-measures-in-the-context-of-covid-19-interim-guidance
- World Health Organization. Vaccine efficacy, effectiveness and protection [Internet]. World Health Organization. 2021 [cited 2022 Jan 28]. Available from: https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection
- Ministry of Health Malaysia COVID-19 Immunisation Task Force. Vaccinations in Malaysia – COVIDNOW [Internet]. 2021 [cited 2021 Dec 3]. Available from: https://covidnow.moh.gov.my/vaccination.
- Thomas SJ, Moreira ED, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761–1773. [cited 2021 Dec 3]. Available from: https://www.nejm.org/doi/10. 1056/NEJMoa2110345
- Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407–1416. [cited 2021 Dec 3]. Available from: http://www.thelancet.com/article/S0140673621021838/fulltext
- Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–1829. [cited 2021 Dec 3]. Available from: http://www.thelancet.com/article/S0140673621009478/fulltext
- Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021; 385(24): e83.
- Suah JL, Seah P, Tok K, et al. PICK-ing Malaysia’ s epidemic apart : effectiveness of a diverse COVID-19 vaccine portfolio. Vaccines. 2021;9:1381.
- Ferguson N, Ghani A, Cori A, et al. Report 49: growth, population distribution and immune escape of Omicron in England [Internet]. London; 2021. Available from: https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-49-Omicron/
- World Health Organization. Interim statement on booster doses for COVID-19 vaccination [Internet]. [cited 2022 Jan 28]. Available from: https://www.who.int/news/item/22-12-2021-interim-statement-on-booster-doses-for-covid-19-vaccination—update-22-december-2021
- Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Heal. 2020;5(9):e475–e483.
- Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
- Siemens Healthcare Diagnositic Inc. Understanding SARS-CoV-2 IgG immunity thresholds and the process of standardization. NY, USA; 2021.
- Ledda C, Costantino C, Motta G, et al. SARS-CoV-2 mRNA vaccine breakthrough infections in fully vaccinated healthcare personnel: a systematic review. Trop Med Infect Dis. 2022;7(1):9. [cited 2022 Jan 25]. Available from: https://www.mdpi.com/2414-6366/7/1/9/htm
- Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun. 2021;12(1):1–5. [cited 2022 Jan 25]. Available from: https://www.nature.com/articles/s41467-021-26672-3
- CodeBlue. Delta 95% Of Covid-19 samples tested in Malaysia: Khairy [Internet]. Code Blue. Kuala Lumpur; 2021 [cited 2021 Nov 24]. Available from: https://codeblue.galencentre.org/2021/10/04/delta-95-of-covid-19-samples-tested-in-malaysia-khairy/
- Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Heal Eur. 2021:100208.
- Ferrari D, Clementi N, Criscuolo E, et al. Antibody titer kinetics and SARS-CoV-2 infections six months after administration with the BNT162b2 vaccine. Vaccines. 2021;9(1357):1–13.
- Eyre DW, Lumley SF, Wei J, et al. Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status. Clin Microbiol Infect. 2021;27(10):1516.e7–1516.e14.
- Duarte LF, Gálvez NMS, Iturriaga C, et al. Immune profile and clinical outcome of breakthrough cases after vaccination with an inactivated SARS-CoV-2 vaccine. Front Immunol. 2021;12:3884.
- Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474–1484.
- Gilbert PB, Montefiori DC, McDermott A, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy trial. Science (80-). 2021;3425, Available from: http://www.ncbi.nlm.nih.gov/pubmed/34401888%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC8366808.
- Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598–1607. DOI:10.1038/s41564-020-00813-8
- Lucas C, Vogels CBF, Yildirim I, et al. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature. 2021: 1–7. [cited 2021 Nov 24]. Available from: https://www.nature.com/articles/s41586-021-04085-y
- Goel RR, Apostolidis SA, Painter MM, et al. Longitudinal analysis reveals distinct antibody and memory B cell responses in SARS-CoV2 naïve and recovered individuals following mRNA vaccination. medRxiv Prepr Serv Heal Sci. 2021. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33688691%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7941668
- Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. The Lancet Microbe. 2021: e240–e249. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254017/pdf/main.pdf
- Cohen KW, Linderman SL, Moodie Z, et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Reports Med. 2021;2: 100354.
- Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200–1204. Available from: https://www.nature.com/articles/s41591-020-0965-6
- Miyamoto S, Arashiro T, Adachi Y, et al. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. medRxiv. 2022; [cited 2022 Jan 28]. Available from: https://www.medrxiv.org/content/10. 1101/2021.12.28.21268481v1